# Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

> **NCT05435274** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 380 (estimated)

## Conditions studied

- Advanced Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** HS-10376

## Key facts

- **NCT ID:** NCT05435274
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-30
- **Primary completion:** 2024-10-07
- **Final completion:** 2025-10-07
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435274, "Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05435274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*